CTX-iPSC platform data shows commerical potential

Source: RNS
RNS Number : 8998S
ReNeuron Group plc
19 November 2021

ReNeuron Group plc

("ReNeuron" or the "Company")


New CTX-iPSC platform data shows potential in Peripheral Nerve Repair


ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces that new data relating to its CTX-derived induced Pluripotent Stem Cell ("CTX-iPSC") platform has been presented this week, showing their commercial potential for the development of mass-scale therapeutics for peripheral nerve repair.


The data has been presented at the 6th world congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS2021), a leading scientific conference taking place in Maastricht, Netherlands.


Ms Rebecca Powell from the University College London ('UCL') Centre for Nerve Engineering presented new data showing for the first time that ReNeuron's CTX-iPSCs can be differentiated to produce Schwann cells, a specific type of support cell that promotes the survival and function of peripheral nerves and importantly, when present in the appropriate three-dimensional configuration, could promote the regrowth of nerve axons damaged by traumatic injury, thus hopefully resulting in the regain of lost functions. The conditional immortalisation cassette present in CTX-iPSCs also promotes a much higher survival of mature Schwann cells.


The abstract from the conference can be found here: https://insight.klinkhamergroup.com/termis2021/book/abstract/878


Professor Stefano Pluchino, Chief Scientific Officer at ReNeuron, commented: "These independently generated results are particularly encouraging as they support the idea that ReNeuron's CTX-iPSCs, initially reprogrammed from a proprietary, conditionally immortalised, well-characterised, clinical grade neural stem cell line, may allow for the potential to scale production of 'off the shelf' allogeneic tissue engineered therapeutics. This makes them a feasible mass-scale solution for areas such as peripheral nerve repair."



The Company has previously presented data demonstrating that its proprietary human CTX neural stem cell line  can be successfully and rapidly reprogrammed to a pluripotent, embryonic stem cell-like state enabling differentiation into any cell type. In essence, this means that the Company is able to take its neural stem cells back to being stem cells that can be made to develop into any other type of cell in the body, including bone, nerve, muscle and skin. Furthermore, CTX-iPSCs also hold the remarkable potential of permitting the scalable manufacture of adult stem cells or tissue progenitor populations for cell therapy.






Olav Hellebø, Chief Executive Officer

Via Walbrook PR

Catherine Isted, Chief Financial Officer




Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)

+44 (0)20 7710 7600

Ben Maddison, Stewart Wallace

Allenby Capital Limited (Joint Broker)

+44 (0)20 3328 5656

James Reeve/George Payne (Corporate Finance)


Stefano Aquilino (Sales & Corporate Broking)




Walbrook PR (Media & Investor Relations)

+44 (0)20 7933 8780 or reneuron@walbrookpr.com

Paul McManus, Alice Woodings

+44 (0)7980 541 893 / +44 (0)7407 804 654


About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments for disease with significant unmet needs. The Company's lead cell therapy candidate is in clinical development for the blindness-causing disease, retinitis pigmentosa.


ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that treat diseases of the central nervous system and other disorders. The Company also has the ability through its conditionally immortalised induced pluripotent stem cell (iPSC) platform to make allogeneic tissue cells of choice; in-house programmes are currently focused on treatments for blood cancers and diabetes.


ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com


This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.